Revolade Tablets Specified Drug-use Survey

This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety
and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric
patients with aplastic anemia (AA). The objective of this survey is to confirm the safety and efficacy of eltrombopag in ATG
treatment naive pediatric patients with AA. Eltrombopag should be administered according
to the dosage and administration specified in the latest version of the package insert.
The observation period is 1 year (364 days) from the start of treatment with this
product, regardless of whether treatment with eltrombopag is continued or not. However,
if hematopoietic stem cell transplantation is performed within 1 year after the start of
treatment with eltrombopag, the observation period shall be until the date of
hematopoietic stem cell transplantation.